Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Immunity ; 57(8): 1939-1954.e7, 2024 Aug 13.
Article in English | MEDLINE | ID: mdl-39013465

ABSTRACT

Antibiotic use in early life disrupts microbial colonization and increases the risk of developing allergies and asthma. We report that mice given antibiotics in early life (EL-Abx), but not in adulthood, were more susceptible to house dust mite (HDM)-induced allergic airway inflammation. This susceptibility was maintained even after normalization of the gut microbiome. EL-Abx decreased systemic levels of indole-3-propionic acid (IPA), which induced long-term changes to cellular stress, metabolism, and mitochondrial respiration in the lung epithelium. IPA reduced mitochondrial respiration and superoxide production and altered chemokine and cytokine production. Consequently, early-life IPA supplementation protected EL-Abx mice against exacerbated HDM-induced allergic airway inflammation in adulthood. These results reveal a mechanism through which EL-Abx can predispose the lung to allergic airway inflammation and highlight a possible preventative approach to mitigate the detrimental consequences of EL-Abx.


Subject(s)
Anti-Bacterial Agents , Asthma , Dysbiosis , Gastrointestinal Microbiome , Indoles , Pyroglyphidae , Animals , Mice , Dysbiosis/immunology , Indoles/pharmacology , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/pharmacology , Gastrointestinal Microbiome/drug effects , Gastrointestinal Microbiome/immunology , Asthma/immunology , Pyroglyphidae/immunology , Lung/immunology , Lung/pathology , Mice, Inbred C57BL , Female , Inflammation/immunology , Disease Models, Animal , Mitochondria/metabolism , Cytokines/metabolism , Hypersensitivity/immunology , Propionates
3.
Front Microbiol ; 13: 857418, 2022.
Article in English | MEDLINE | ID: mdl-35591998

ABSTRACT

The gut microbiome engages in constant interactions with the immune system, laying down the fundamentals of what we perceive as health or disease. The gut microbiota acts locally in the intestines and distally in other organs, such as the lungs. This influence (termed "the gut-lung axis") constitutes the basis for harnessing the microbiome to prevent or treat chronic respiratory diseases. Within this context, two approaches gained the most attention: the diet interventions (which shape the microbiome) and the probiotics (which exert beneficial effects directly on the host). Microbial products, which constitute a means of communication along the gut-lung axis, are only now emerging as a new class of potential therapeutics. Here, we provide a comprehensive overview of microbial products active in the airways, describe the immunological mechanisms they trigger, and discuss their clinical advantages and pitfalls.

4.
Front Immunol ; 13: 949033, 2022.
Article in English | MEDLINE | ID: mdl-36052074

ABSTRACT

Host-microbiota interactions are bidirectional. On one hand, ecological pressures exerted by the host shape the composition and function of the microbiota. On the other, resident microbes trigger multiple pathways that influence the immunity of the host. Bile acids participate in both parts of this interplay. As host-derived compounds, they display bacteriostatic properties and affect the survival and growth of the members of the microbial community. As microbiota-modified metabolites, they further influence the microbiota composition and, in parallel, modulate the immunity of the host. Here, we provide a comprehensive overview of the mechanisms behind this unique dialogue and discuss how we can harness bile acids to treat intestinal inflammation.


Subject(s)
Gastrointestinal Microbiome , Microbiota , Bile Acids and Salts
SELECTION OF CITATIONS
SEARCH DETAIL